Ritonavir Viatris (previously Ritonavir Mylan) (ritonavir)
Generic
- Region
- 🇪🇺 EU
- Active substance
- ritonavir
- Company
- Viatris Limited
- Status
- Authorised
- Therapeutic area
- HIV Infections
- CHMP opinion
- Thu 14 Sep 2017
- EU approval
- Thu 09 Nov 2017
- Designations
- Generic
- Application
- EMEA/H/C/004549
- ATC
- J05AE03
- Official record
- www.ema.europa.eu
Indication
Ritonavir is indicated as a pharmacokinetic enhancer of co-administered protease inhibitors as part of antiretroviral combination therapy in human immunodeficiency virus-1 (HIV-1) infected patients (adults and children of 2 years of age and older).
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Paxlovid Authorised · Pfizer Europe MA EEIG
- 🇪🇺 Lopinavir/Ritonavir Viatris (previously Ritonavir Mylan) Authorised · Viatris Limited
- 🇪🇺 Norvir Authorised · AbbVie Deutschland GmbH & Co. KG
- 🇪🇺 Kaletra Authorised · AbbVie Deutschland GmbH & Co. KG
- 🇪🇺 Viekirax Withdrawn · AbbVie Deutschland GmbH & Co. KG
Follow Ritonavir Viatris (previously Ritonavir Mylan)
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.